Senior Machine Learning Engineer, Deep Genomics
Offers stock ownership
AI powered RNA therapy discovery
Job no longer available
AI powered RNA therapy discovery
101-200 employees
Job no longer available
Offers stock ownership
101-200 employees
Company mission
To untangle the complexity in RNA biology, and evaluates thousands of possibilities to identify the best therapeutic candidates.
Jump to section
Company mission
To untangle the complexity in RNA biology, and evaluates thousands of possibilities to identify the best therapeutic candidates.
-22% employee growth in 12 months
Our take
Deep Genomics uses AI to analyze genetic data with the aim of discovering and producing RNA-based genetic medicines. The company is currently running a series of programs with the aim of advancing to clinical trials in the near future.
RNA medical technology has been in development for over 40 years but never became mainstream, but the launch of BioNTech/Pfizer’s Covid-19 vaccine threw it into the public spotlight. And this is set to accelerate the production of more and more RNA-based therapeutics, supplemented by AI which can quickly mine dense biological data to better evaluate potential candidates.
With its financial backing in the hundreds of millions, Deep Genomics now intends to radically boost its headcount and roll out more therapeutic discovery programs.
Kirsty
Company Specialist at Welcome to the Jungle
Funding (last 2 of 4 rounds)
Jul 2021
$180m
SERIES C
Jan 2020
$40m
SERIES B
Total funding: $236.8m
This company has top investors
Leadership
Brendan Frey, Ph.D.
(Founder, CIO & Board Member)Professor of Engineering and Medicine at the University of Toronto. Co-founded the Vector Institute for Artificial Intelligence. They have carried out pioneering work in the fields of deep learning, genomic medicine, and information technology.
Brian O'Callaghan
(CEO & Board Member)Brian is an experienced CEO having previously served at ObsEva, Petra Pharma Corporation, Sonrgy, Acucela, and Sangart.